Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Pfizer
Pfizer
Merck Sharp & Dohme LLC
Pfizer
Compass Therapeutics
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Pheon Therapeutics
Eli Lilly and Company
Incyte Corporation
BigHat Biosciences, Inc.
Travera Inc
Revolution Medicines, Inc.
Pfizer
Seagen Inc.
Turning Point Therapeutics, Inc.
Alterome Therapeutics, Inc.
GlaxoSmithKline
Aesculap AG